The American Diabetes Association's 86th Scientific Sessions concluded Monday in New Orleans after four days of data that shifted the floor on what obesity pharmacotherapy can achieve. More than 12,000 physicians and researchers from over 115 countries arrived at the Ernest N. Morial Convention Center expecting landmark readouts — and the pipeline delivered. Eli Lilly's triple-agonist retatrutide posted surgical-level weight loss numbers confirmed by simultaneous journal publication, Boehringer Ingelheim's survodutide opened a second front in fatty liver disease, Pfizer's monthly injectable berobenatide made its Phase 2b debut, and the amylin analog class staged a credible comeback. For any clinician setting formulary expectations or any patient watching the obesity drug race, what was confirmed in New Orleans this week will be the raw material for coverage decisions over the next 18 months.
The conference — which also ran virtually — spans over 200 sessions across 25 topic areas. But the headline was unmistakably the parade of Phase 3 readouts for next-generation agents, each competing to define the post-semaglutide era of metabolic care, and each arriving as full data on a disease affecting more than two in five American adults.
Retatrutide Weight Loss Results Reach Bariatric Threshold
The most consequential data of the meeting came from Eli Lilly's retatrutide TRIUMPH-1 trial, presented in a full symposium Saturday and simultaneously published in advance of the conference. At the 12 mg dose over 80 weeks, 2,339 randomized participants lost an average of 70.3 lbs — 28.3% of body weight — versus 2.2% on placebo. Crucially, 45.3% of participants on the highest dose crossed the 30% weight-loss threshold, a level benchmarked to outcomes from bariatric surgery.
In a pre-specified blinded extension, 532 participants with a baseline BMI of 35 or higher who continued on retatrutide through 104 weeks lost an average of 85 lbs, or 30.3% of body weight — a figure that for the first time brings a pharmacological agent into direct numerical parity with sleeve gastrectomy and gastric bypass outcomes. The extension showed no plateau, meaning weight loss continued progressing between weeks 80 and 104 at the highest doses. Lilly also presented data from the TRANSCEND-T2D-1 trial in type 2 diabetes, simultaneously published in The Lancet, which showed retatrutide lowered HbA1c by up to 2.0% and reduced weight by up to 16.8% at 40 weeks. Results from nested basket trials within TRIUMPH-1 — covering knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea — extended the drug's potential clinical footprint considerably.
Tolerability carries real caveats. Discontinuation rates due to adverse events climbed with dose: 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, versus 4.9% on placebo. Nausea affected 42.4% at the highest dose; vomiting, 25.3%; and dysesthesia, an abnormal skin sensation, reached 12.5% versus 0.9% on placebo. Session moderator Prof. Naveed Sattar of the University of Glasgow noted publicly that the data were exciting but cautioned that rapid weight reduction at scale may introduce risks not yet fully characterized.
Triple Agonist Mechanism: Why Adding Glucagon Broke the Ceiling
Retatrutide's mechanism is what separates it architecturally from every prior drug in this class. Approved GLP-1 agents like semaglutide (Wegovy) activate a single receptor; tirzepatide (Zepbound), the current top-selling agent, activates two — GLP-1 and GIP. Retatrutide adds a third: the glucagon receptor, making it the first triple agonist — targeting GLP-1, GIP, and glucagon — to reach Phase 3.
Each receptor target contributes a distinct metabolic pathway. GLP-1 receptor activation suppresses appetite by acting on hunger-regulating neurons in the hypothalamus, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. GIP receptor agonism amplifies insulin response, may reduce nausea at higher doses (a counterintuitive but documented effect), and appears to enhance the metabolic effects of GLP-1 agonism synergistically. The glucagon receptor contribution is where retatrutide departs from its predecessors: glucagon receptor agonism in isolation would normally raise blood glucose by triggering hepatic glucose output. But in retatrutide's three-receptor design, the insulinotropic effects of GLP-1 and GIP counterbalance that glycemic impact while preserving the glucagon receptor's metabolic-rate-enhancing effects — specifically, increased thermogenesis and accelerated lipolysis, the breakdown of stored fat into usable energy.
Preclinical research and Phase 2 data both suggested this three-receptor balance would produce meaningfully more weight loss than dual agonism, because resting metabolic rate would be elevated rather than suppressed as weight falls — a departure from the adaptive thermogenesis that normally slows weight loss over time. TRIUMPH-1 confirms that the mechanistic hypothesis holds at scale: 30.3% average weight loss at two years, without a plateau, in patients who represent the obesity severity typically associated with surgical intervention.
No FDA submission for retatrutide has been filed as of today. Lilly has seven additional Phase 3 readouts expected before year's end, including TRIUMPH-2 in obesity plus type 2 diabetes and TRIUMPH-3 in obesity plus established cardiovascular disease.
Survodutide's Dual-Receptor Design Targets Liver Fat, Not Just Weight
Boehringer Ingelheim and Zealand Pharma delivered the full SYNCHRONIZE-1 results here, with data simultaneously appearing in The New England Journal of Medicine. Survodutide, a glucagon/GLP-1 dual agonist, achieved up to 16.6% average weight loss after 76 weeks in participants without type 2 diabetes — broadly on par with semaglutide but below retatrutide's triple-receptor numbers. Up to 85.1% of survodutide-treated patients lost at least 5% of body weight, versus 38.8% on placebo. Critically, weight reduction was driven predominantly by fat tissue rather than lean mass — a key clinical distinction for the obesity field's long-standing concern about muscle loss.
Where survodutide generated the most attention from liver disease specialists was in a body-composition sub-study of SYNCHRONIZE-1 and in the SYNCHRONIZE-MASLD trial results simultaneously published in Nature Medicine. The sub-study showed survodutide reduced visceral fat — the metabolically harmful abdominal fat closely linked to insulin resistance and cardiovascular risk — by up to 34% at week 76. Liver fat, measured by MRI, fell by up to 63.1%. In SYNCHRONIZE-MASLD, which enrolled 218 adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation or fibrosis, survodutide met both co-primary endpoints: up to 84.2% of treated participants achieved at least 30% relative liver fat reduction, and liver fat normalization — defined as liver fat content below 5% — was reached by 6 in 10 treated participants at 48 weeks.
The glucagon receptor mechanism is what drives this liver effect. Glucagon agonism acts directly on hepatocytes to reduce liver fat accumulation, regulate metabolic function, and is thought to resolve inflammation and improve fibrosis — functions that GLP-1 agonism alone does not accomplish. This is the specific engineering reason a GLP-1/glucagon dual agonist may outperform GLP-1 monotherapy in MASLD, even when overall weight loss is comparable. Up to 75% of people with obesity develop MASLD, and roughly a third of those advance to metabolic dysfunction-associated steatohepatitis (MASH), which can progress to cirrhosis and liver failure. With no widely used pharmacological standard of care for MASLD, survodutide's liver profile creates a potential commercial niche independent of where it finishes on the overall obesity efficacy leaderboard.
The discontinuation data drew scrutiny. In SYNCHRONIZE-1, 19% of survodutide-treated patients discontinued due to gastrointestinal adverse events, versus 2.9% on placebo. Boehringer characterized the GI events as mild to moderate and concentrated during dose escalation; the company has signaled plans for optimized patient-centered dosing protocols in response.
Pfizer's Monthly GLP-1: Albumin Binding Extends Half-Life to 30 Days
Pfizer used the ADA meeting to stage a full Phase 2b debut for berobenatide (PF-08653944), a potential first-in-class monthly GLP-1 receptor agonist acquired through its $10 billion purchase of Metsera. The molecular engineering behind berobenatide's monthly dosing interval is not a reformulation of existing GLP-1 peptides; it is a structurally distinct design built around albumin binding.
Standard GLP-1 drugs — including semaglutide — are broken down by the body within approximately seven days, necessitating weekly injections. Berobenatide is engineered to bind tightly to albumin, the most abundant protein in human blood plasma, through a process that uses terminal lipidation. This albumin attachment protects the molecule from enzymatic degradation and renal clearance, dramatically extending its circulating half-life. The drug is also a "fully biased" GLP-1 receptor agonist, meaning it preferentially activates cyclic adenosine monophosphate (cAMP) signaling over the beta-arrestin pathway. That signaling bias inhibits receptor internalization — the process by which receptors are pulled back inside cells and become temporarily unavailable — which is thought to prolong efficacy and may contribute to the drug's tolerability profile by reducing receptor desensitization.
In VESPER-1, patients who escalated to 2.4 mg weekly berobenatide achieved non-placebo-adjusted weight loss of approximately 16% at week 32 with no plateau observed. VESPER-3 — which tested the transition from weekly to monthly dosing — showed placebo-adjusted weight loss of up to 12.3% at 28 weeks on the 4.8 mg monthly dose. In VESPER-2, the Type 2 diabetes cohort, berobenatide produced a 2.2% reduction in HbA1c versus 0.2% change on placebo at 28 weeks. Tolerability was favorable: low gastrointestinal adverse events and low discontinuation rates were reported even under rapid dose escalation without a step-down option, which Pfizer characterized as an advantage over competitors.
Analysts struck a measured tone. The efficacy numbers from Phase 2b sit below the current leaders — 12–16% non-placebo-adjusted at comparable durations versus retatrutide's 28%+ and tirzepatide's 20%+ at Phase 3 scale. The differentiating case for berobenatide rests primarily on dosing convenience: a once-monthly injection could meaningfully improve real-world adherence for a condition that requires indefinite treatment. Pfizer plans 10 Phase 3 studies for berobenatide in 2026, including the VESPER-6 pivotal trial for monthly maintenance dosing. The company has also indicated it intends to launch a direct-to-consumer cash-pay option at market entry.
Amylin Analogs and GLP-1 Combination Pipelines
Away from the headline Phase 3 readouts, a quieter story developed around amylin analogs. Zealand Pharma and Roche presented Phase 2 data from the ZUPREME-1 trial of petrelintide, a once-weekly amylin analog. Participants achieved clinically meaningful reductions in body weight versus placebo over 42 weeks, and both companies featured the data in a dedicated symposium on amylin as a novel diabetes and obesity therapy. The amylin pathway works through a distinct mechanism from incretin-based agents: amylin, co-secreted with insulin by pancreatic beta cells, slows gastric emptying, suppresses postprandial glucagon, and acts on the area postrema in the brain to reduce food intake — complementary rather than overlapping with GLP-1 receptor signaling. The clinical hypothesis is that combining amylin and GLP-1 pathways could achieve additive weight reduction while distributing the tolerability burden across mechanisms, potentially reducing GI side effects relative to high-dose GLP-1 monotherapy.
Ascletis Pharma presented multiple datasets from its metabolic pipeline, including Phase 2b data for ASC30, an oral GLP-1 receptor agonist tablet showing dose-dependent weight loss with a favorable gastrointestinal tolerability profile. The company announced plans to initiate global Phase 3 trials for ASC30 by the end of Q3 2026. The breadth of international submissions at this year's meeting — from Chinese, Irish, and European companies alongside the major American and Danish players — underscored how thoroughly the obesity drug race has become a global industrial competition.
ADA Standards and Pipeline Coverage Decisions
The clinical context for all of this data extends beyond individual trials. Earlier in 2026, the ADA's Obesity Association published the inaugural pharmacologic treatment section of its Standards of Care in Overweight and Obesity, the first time the organization issued dedicated obesity pharmacotherapy guidance separate from its annual diabetes standards. That document, which includes 34 new recommendations spanning medication selection, goal setting, long-term management, and special populations, is already being used by payers and health systems as an anchor for clinical appropriateness criteria.
For clinicians and coverage decision-makers, the 2026 ADA Scientific Sessions will be remembered as the meeting where the benchmarks for "effective" changed. Retatrutide's surgery-level numbers demand a rethinking of what pharmacological obesity treatment can achieve. Survodutide's liver data open a second therapeutic front. Berobenatide's monthly dosing, if it holds through Phase 3, addresses a real adherence gap that affects the entire class. The harder question — which drugs survive to commercial practice at accessible prices — will play out over the next 18 months as FDA submissions accumulate and payers begin drawing their formulary red lines. None of the drugs highlighted in New Orleans this week has received FDA approval. The data generated here are the evidence on which those decisions will rest.
Frequently Asked Questions
How much weight does retatrutide cause patients to lose?
In the Phase 3 TRIUMPH-1 trial, participants on the highest dose of 12 mg lost an average of 70.3 lbs, representing 28.3% of body weight, over 80 weeks. In a pre-specified extension for participants with severe obesity who continued for two years, average weight loss reached 85 lbs, or 30.3% — a level previously associated only with bariatric surgery outcomes.
What is a triple agonist obesity drug?
A triple agonist simultaneously activates three hormone receptors involved in metabolism. Retatrutide targets GLP-1, GIP, and glucagon receptors in a single molecule. GLP-1 and GIP receptor agonism reduces appetite and improves insulin response; glucagon receptor agonism increases resting metabolic rate and accelerates fat breakdown. This three-pathway combination is what distinguishes retatrutide from dual agonists like tirzepatide, which targets GLP-1 and GIP, and single agonists like semaglutide, which targets only GLP-1.
What weight loss drugs are in Phase 3 trials for obesity in 2026?
Multiple agents with Phase 3 data in 2026 include retatrutide (Eli Lilly), survodutide (Boehringer Ingelheim/Zealand Pharma), and berobenatide (Pfizer, in Phase 3). Novo Nordisk's CagriSema was submitted for FDA review in late 2025. None of these candidates — except Eli Lilly's oral GLP-1 Foundayo, approved in spring 2026 — has yet received FDA approval for obesity.
Does survodutide reduce liver fat?
Yes. In both a sub-study of the SYNCHRONIZE-1 trial and the separate SYNCHRONIZE-MASLD Phase 3 trial, survodutide demonstrated meaningful reductions in liver fat. SYNCHRONIZE-MASLD showed that 6 in 10 treated patients with metabolic dysfunction-associated steatotic liver disease reached liver fat normalization at 48 weeks. Visceral fat was reduced by up to 34% and liver fat by up to 63% in the SYNCHRONIZE-1 body-composition sub-study.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
